Oct 24, 2025
The chronic pruritus drugs market is currently not highly competitive, with only a few chronic pruritus drugs approved for treatment, including KORSUVA/KAPRUVIA (Cara Therapeutics/CSL/ Vifor/Maruishi), LIVMARLI (Mirum Pharmaceuticals/Takeda), and BYLVAY/KAYFANDA (Mirum Pharmaceuticals/Takeda). However, the treatmen...
Read More...
Oct 13, 2025
Chronic pruritus, characterized by itching that persists for more than six weeks, is a multifaceted condition that may stem from dermatologic, systemic, neurologic, or psychogenic factors. It has a profound impact on patients’ quality of life and is increasingly recognized as a standalone clinical entity. DelveInsi...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper